Dogwood Therapeutics, Inc.

NasdaqCM:DWTX Stock Report

Market Cap: US$10.2m

Dogwood Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DWTX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders74,8123.91%
Institutions151,7907.94%
Public Companies211,38311.1%
General Public1,473,14377.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 148.1%.

Top Shareholders

Top 24 shareholders own 22.92% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.1%
CK Life Sciences Int'l., (Holdings) Inc.
211,383US$1.1m2,400%no data
3.65%
Orca Capital GmbH, Asset Management Arm
69,821US$371.4k0%10.04%
1.85%
Brian Corday
35,296US$187.8k0%no data
1.59%
William Pridgen
30,451US$162.0k0%no data
1.56%
UBS Asset Management AG
29,818US$158.6k68.7%no data
0.75%
Geode Capital Management, LLC
14,409US$76.7k31.8%no data
0.65%
FNY Investment Advisers, LLC
12,500US$66.5k0%0.05%
0.62%
The Vanguard Group, Inc.
11,782US$62.7k41%no data
0.59%
Hudson River Trading LLC, Asset Management Arm
11,228US$59.7k0%no data
0.31%
Richard Burch
5,907US$31.4k0%no data
0.12%
Gregory Duncan
2,298US$12.2k0%no data
0.055%
Tower Research Capital Europe Limited
1,050US$5.6k8.02%no data
0.031%
Morgan Stanley, Investment Banking and Brokerage Investments
600US$3.2k0%no data
0.027%
David Keefer
512US$2.7k0%no data
0.012%
Strategic Advisers LLC
225US$1.2k0%no data
0.0098%
SBI Holdings Inc., Asset Management Arm
188US$1.0k2,250%no data
0.0084%
Abel De La Rosa
160US$851.00%no data
0.0063%
Angela Walsh
120US$638.50%no data
0.0063%
Activest Wealth Management, LLC
120US$638.50%no data
0.0021%
John Thomas
40US$212.50%no data
0.0016%
BlackRock, Inc.
30US$159.60%no data
0.0015%
Richard Whitley
28US$149.50%no data
0.00052%
Bank of America Corporation, Asset Management Arm
10US$52.90%no data
0.00047%
Group One Trading LP, Asset Management Arm
9US$47.8-80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 20:43
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dogwood Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean LeeH.C. Wainwright & Co.
Jason McCarthyMaxim Group
David BautzZacks Small-Cap Research